Elon Musk is looking to invest in a rival to his brain-computer startup Neuralink.
The billionaire is said to have approached the CEO of Synchron, the company developing brain implants, about the possibility of buying shares, based on Reuters, citing four sources familiar with the matter.
The report said it was not yet clear whether Thomas Oxley, CEO of Synchron would accept an offer.
Neuralink is trying to catch up with Synchron, which started in July USA’s first human trial its technology. The trial involved implanting its device in the first of six patients. The first patient had ALS, a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. The goal is for the device to translate a patient’s thoughts into actions — including online browsing and email communication — through commands sent to a computer.
Synchron’s human trial is the second. First performed in Australia with four patients with no negative side effects and able to communicate and purchase online, Bloomberg report.
Neuralink, founded in 2016, has yet to begin human trials. And it’s unclear at what stage the company is applying to the U.S. Food and Drug Administration for approval to begin human trials, the report said.
Both startups want to create technology that, in layman’s terms, turns thoughts into action for those whose mobility or speech has been affected.
Synchron and Neuralink not responding immediately Fortune’s Request comments.
Former and current employees told Reuters that Musk was frustrated by Neuralink’s slow development of its technology, and that contacting Oxley came after he made clear his frustrations. . Tension in Neuralink is not new, like Luck before report.
Neuralink’s former chairman, Max Hodak, left the company after serving at the helm since its founding and is now an investor in Synchron.
Register Fortune feature email list so you don’t miss our biggest features, exclusive interviews and surveys.